Valuation: Omeros Corporation

Market Cap 1.24B 1.07B 1.01B 918M 1.73B 119B 1.76B 11.83B 4.63B 59.59B 4.67B 4.57B 198B P/E 2026 *
19.3x
P/E 2027 * 17.2x
Enterprise Value 1.24B 1.07B 1.01B 918M 1.73B 119B 1.76B 11.83B 4.63B 59.59B 4.67B 4.57B 198B EV / Sales 2026 *
9.91x
EV / Sales 2027 * 6.29x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.92%
1 week+29.74%
Current month+45.19%
1 month+63.71%
3 months+29.44%
6 months+47.05%
Current year+0.09%
1 week 13
Extreme 13
18.14
1 month 9.12
Extreme 9.12
18.14
Current year 6.7
Extreme 6.7023
18.14
1 year 3.94
Extreme 3.94
18.14
3 years 0.92
Extreme 0.92
18.14
5 years 0.92
Extreme 0.92
18.14
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap.
7/22/26 Free

Chief Financial Officer

105,000 0.1451%
7/22/26 Free

General Counsel

105,000 0.1451%
7/22/26 Free

Chief Executive Officer

1,000,000 1.3817%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%+29.74%+317.23%+330.83% 1.24B
-1.90%+2.85%+61.37%+102.88% 70.07B
-3.21%-4.32%+31.19%+59.75% 52.87B
-2.05%-5.61%-3.14%+454.89% 27.02B
-1.27%-1.57%+46.46%+6.09% 23.61B
+1.05%-0.62%-17.40%-13.36% 23.38B
+3.81%+20.97%+263.48%+552.47% 19.43B
+0.10%+1.40%+38.98%-20.04% 18.75B
-0.95%-3.52%+20.04%+613.01% 15.85B
+1.24%-5.23%+33.19%+138.21% 12.7B
Average -0.41%+4.72%+79.14%+222.47% 26.49B
Weighted average by Cap. -1.09%+0.69%+51.10%+168.86%

Financials

2026 *2027 *
Net sales 126M 108M 102M 92.71M 174M 12.01B 177M 1.19B 467M 6.01B 472M 461M 19.99B 198M 171M 161M 146M 274M 18.91B 279M 1.88B 735M 9.47B 743M 727M 31.48B
Net income 63.3M 54.67M 51.37M 46.72M 87.84M 6.05B 89.29M 602M 235M 3.03B 238M 233M 10.07B 79.47M 68.64M 64.5M 58.66M 110M 7.6B 112M 756M 295M 3.81B 298M 292M 12.65B
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-08-14 US$17.19 -0.92% 3,675,975
26-08-13 US$17.35 +26.55% 13,436,012
26-08-12 US$13.71 +0.81% 3,583,213
26-08-11 US$13.60 -0.15% 1,888,088
26-08-10 US$13.62 +2.79% 1,390,698
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
17.19USD
Average target price
33.00USD
Spread / Average Target
+91.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock